Business
-
CDMO Bespak and DevPro Biopharma have revealed their partnership on development of DevPro’s DP007 albuterol MDI, which is formulated with Honeywell’s Solstice Air HFO-1234ze(E) propellant. According to the companies, DP007 is expected to provide a… Read more . . .
-
Gossamer Bio and Chiesi Farmaceutici have partnered to develop and commercialize Gossamer’s seralutinib inhalation powder for the treatment of pulmonary hypertension, the companies announced. Chiesi, which will get 50% of US commercial profit and ex-US rights… Read more . . .
-
ARS Pharmaceuticals announced has submitted its Day 180 response regarding the company’s MAA for Neffy epinephrine nasal spray to the EMA’s Committee for Medicinal Products for Human Use (CHMP) and expects an opinion on the… Read more . . .
-
Amneal Pharmaceuticals announced that it has launched a generic over-the-counter naloxone nasal spray for the reversal of opioid overdose after its ANDA for the product was approved by the FDA. Amneal had announced the agency’s… Read more . . .
-
Firebrick Pharma announced that it has launched Nasodine povidone-iodine nasal spray in the US via direct sales through a web site. The company said that it will not make any therapeutic claims so that the… Read more . . .
-
According to Orexo, the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,957,647 (“Pharmaceutical composition comprising adrenaline”), which covers Orexo’s OX640 epinephrine nasal powder product. The USPTO previously issued US patent… Read more . . .
-
Inhalation CDMO Vectura has partnered with Mundipharma to reformulate Flutiform fluticasone propionate / formoterol fumarate MDI using a lower global warming potential (LGWP) propellant, the companies announced. According to the announcement, the first step in the reformulation… Read more . . .
-
Silo Pharma announced that it will exercise an option for an exclusive worldwide license to develop SPC-14, an intranasal therapy for the treatment of Alzheimer’s disease, from Columbia University. Silo says that it expects the… Read more . . .
-
The Cystic Fibrosis Foundation announced that it making an additional investment of up to $8.5 million to support a Phase 2 trial of SpliSense’s nebulized SPL84 antisense oligonucleotide in patients with cystic fibrosis associated with the… Read more . . .
-
Acorda Therapeutics announced that it has filed to begin Chapter 11 bankruptcy proceedings and said that Merz Therapeutics will serve as a “stalking horse” bidder for Acorda’s assets, including the rights to Inbrija inhaled dry… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland